Figure 2
From: Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
Inhibition of mammary carcinogenesis in FVB-huHER2 mice by anti-HER2 vaccines. (a) Tumor-free survival (*P < 0.05 vs. mock group by Mantel-Haenszel analysis). (b) Tumor multiplicity (mean number ± SEM) (*P < 0.05 vs. mock vaccination group by Student’s t-test). (c) Whole-mount section of the fourth mammary gland of control (left panel) or vaccinated (right panel) mice at 60 weeks of age. L = lymph node. Mock: The results in the control groups (untreated, vehicle and pVAX1) were not significantly different, and the data were cumulated (n = 31). HER2-cell vaccine (n = 8); HuRT-DNA vaccine (n = 12). FVB-huHER2, FVB mice transgenic for huHER2; HuRT, chimeric human/rat HER2 plasmid electroporated vaccine.